Clinical Trial: A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07382739) titled 'A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"' on Jan. 26.

Brief Summary: To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.

Study Start Date: July 14, 2026

Study Type: INTERVENTIONAL

Condition: Phase 2 Radiotherapy-Induced Immune Priming Elranatamab Relapsed Refractory Multiple Myeloma (RRMM) Extramedullary Disease in Multiple Myeloma Paramedullary Disease PMD

Intervention: DRUG: Elranatamab ...